ArticleClinical and experimental nephrology2026
Initial treatment patterns of primary membranoproliferative glomerulonephritis in Japan (2017-2021): an updated analysis based on nationwide personal clinical records.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPrimary membranoproliferative glomerulonephritis (MPGN) is a rare progressive kidney disease that often leads to end-stage kidney disease. Our previous nationwide registry study (Report 1, 2015-2018) characterized initial demographics and treatment patterns. In this study (Report 2), we aimed to update these findings, focusing on newly registered cases (2017-2021).
methodsPersonal clinical records of patients with primary MPGN between 2017 and 2021 were obtained from the national registry organized by the Japanese Ministry of Health, Labour and Welfare. Characteristics of primary MPGN throughout Japan were investigated.
resultsA total of 210 patients (median age, 49 years; male, 51%) with newly registered primary MPGN were identified. Nephrotic syndrome was present in 83.8% of patients at enrollment. Initial treatment frequently included corticosteroids (63.8%), with a modest increase in intravenous methylprednisolone pulse therapy (41.4%) compared with that in Report 1. The incidence of hemodialysis was 7.1%. Compared with those in Report 1, the demographic patterns were similar; however, nephrotic presentations were more common. Cyclosporine and mizoribine usage were significantly higher in the pediatric group (< 18 years, n = 44) compared to the corresponding usage in the older adult group (≥ 65 years, n = 75). The mean dosage of oral prednisolone and other immunosuppressants during initial treatment did not differ among the four age groups.
conclusionCompared with the earlier report (Report 1), patients with newly registered primary MPGN presented with nephrotic syndrome more often, highlighting the continued risk of poor prognosis and the need for more refined therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.